Research article · 15 Apr 2026
Conference abstractPublished 26 Jun 2014
Hepatorenal syndrome
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
H epatorenal syndrome (HRS) is a life threatening complication that affects individuals with cirrhosis (regardless of cause), severe alcoholic hepatitis, or fulminant hepatic failure, and usually occurs when liver function deteriorates rapidly because of an acute injury such as an infection, bleeding in the gastrointestinal tract, or overuse of diuretic medications. Renal failure in patients with cirrhosis is primarily related to disturbances in circulatory function triggered by portal hypertension. Arterial vasodilatation occurrs because of increased production or activity of vasodilator factors particularly nitric oxide in the splanchnic circulation. In the early stages of cirrhosis, increased cardiac output compensates for a modest reduction in systemic vascular resistance, permitting the arterial pressure and effective arterial blood volume to remain within normal limits. In advanced stages of cirrhosis, systemic vascular resistance is markedly reduced, and additional increases in cardiac output cannot compensate, leading to underfilling of the arterial circulation. Mortality among patients with hepatorenal syndrome is very high. Therefore, liver transplantation should be considered in all patients who have no contraindications to this procedure, and it should be performed as early as possible, because severe renal failure is predictive of a poor outcome after transplantation. Treatment of the hepatorenal syndrome with albumin and the vasopressin analogue terlipressin before transplantation may improve the post-transplantation outcome.
Subjects
Nephrology & UrologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Nephrology & Therapeutics.
Brief report · 30 Mar 2026
Renal Fibrosis: Targeting Pathways For New Therapies
Brief report · 30 Mar 2026
SGLT2 Inhibitors: A New Era for Diabetic Kidney Disease
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Nephrology & Therapeutics
- SubjectNephrology & Urology
- BylineArticles whose byline prints “Salwa lbrahim”

